Dose-response relationship in phase I clinical trials: A European Drug Development Network (EDDN) collaboration study

Clinical Cancer Research

Volumn 20, Issue 22, 2014, Pages 5663-5671

  García, Victor Moreno ^a,b,q   Olmos, David ^a,b,r   Gomez Roca, Carlos ^c   Cassier, Philippe A ^a,b,s   Morales Barrera, Rafael ^d   Del Conte, Gianluca ^e   Gallerani, Elisa ^f   Brunetto, Andre T ^a   Schöoffski, Patrick ^g   Marsoni, Silvia ^h,i   Schellens, Jan H M ^j   Penel, Nicolas ^k   Voest, Emile ^l   Evans, Jeffrey ^m   Plummer, Ruth ⁿ   Wilson, Richard H ^o   Soria, Jean Charles ^c   Tabernero, Josep ^d   Verweij, Jaap ^p   Kaye, Stan B ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h Southern Europe New Drug Organization (SENDO) Foundation   (Italy)

ⁱ Istituto di Candiolo Fondazione del Piemonte Per l'Oncologia IRCCS   (Italy)

^j NETHERLANDS CANCER INSTITUTE   (Netherlands)

^k CENTRE OSCAR LAMBRET   (France)

^l UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^m UNIVERSITY OF GLASGOW   (United Kingdom)

ⁿ FREEMAN HOSPITAL   (United Kingdom)

^o QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^p ERASMUS MEDICAL CENTER   (Netherlands)

^q South Texas Accelerated Research Therapeutics   (Spain)

^r Centro Nacional de Investigaciones Oncológicas   (Spain)

^s CENTRE LÉON BÉRARD   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CONTROL; CANCER GROWTH; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; COLORECTAL CANCER; CONNECTIVE TISSUE TUMOR; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG MEGADOSE; EUROPE; FEMALE; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HUMAN; LOW DRUG DOSE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MESOTHELIOMA; METASTASIS; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; SARCOMA; SOLID TUMOR; TREATMENT RESPONSE; UROGENITAL TRACT CANCER; VERY ELDERLY; ADOLESCENT; DRUG MONITORING; FACTUAL DATABASE; MIDDLE AGED; MORTALITY; NEOPLASMS; PATHOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84918595093     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0719     Document Type: Article

References (19)

1. Critical role of phase I clinical trials in cancer treatment. American Society of Clinical Oncology. J Clin Oncol 1997;15:853-9.
2. Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981;304:10-5.
3. Von Hoff DD, Turner J. Response rates, duration of response, and dose response effects in phase I studies of antineoplastics. Invest New Drugs 1991;9:115-22.
4. Agrawal M, Emanuel EJ. Ethics of phase 1 oncology studies: reexamining the arguments and data. JAMA 2003;290:1075-82.
5. Jain RK, Lee JJ, Hong D, Markman M, Gong J, Naing A, et al. Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res 2010;16:1289-97.
6. Postel-Vinay S, Arkenau HT, Olmos D, Ang J, Barriuso J, Ashley S, et al. Clinical benefit in phase-I trials of novel molecularly targeted agents: does dose matter? Br J Cancer 2009;100:1373-8.
7. Olmos D, A'Hern RP, Marsoni S, Morales R, Gomez-Roca C, Verweij J, et al. Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors. J Clin Oncol 2012;30:996-1004.
8. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
9. Penel N, Kramar A. What does a modified-Fibonacci dose-escalation actually correspond to? BMC Med Res Methodol 2012;12:103.
10. Ferte C, Soria JC, Penel N. Dose-levels and first signs of efficacy in contemporary oncology phase 1 clinical trials. PLoS ONE 2011;6:e16633.
11. Gupta S, Hunsberger S, Boerner SA, Rubinstein L, Royds R, Ivy P, et al. Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials. J Natl Cancer Inst 2012;104:1860-6.
12. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19.
13. Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009;361:1164-72.
14. Postel-Vinay S, Gomez-Roca C, Molife LR, Anghan B, Levy A, Judson I, et al. Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities? J Clin Oncol 2011;29:1728-35.
15. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22:909-18.
16. Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 2009;27:5601-6.
17. Parulekar WR, Eisenhauer EA. Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. J Natl Cancer Inst 2004;96:990-7.
18. de Bono JS, Ashworth A. Translating cancer research into targeted therapeutics. Nature 2010;467:543-9.
19. Garcia VM, Cassier PA, de Bono J. Parallel anticancer drug development and molecular stratification to qualify predictive biomarkers: dealing with obstacles hindering progress. Cancer Discov 2011;1:207-12.